During the last three months, 25 analysts shared their evaluations of ACADIA Pharmaceuticals ACAD, revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 12 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 7 | 8 | 3 | 0 | 0 |
| 2M Ago | 0 | 3 | 1 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for ACADIA Pharmaceuticals, presenting an average target of $33.37, a high estimate of $42.00, and a low estimate of $19.00. A decline of 8.65% from the prior average price target is evident in the current average.
Analyzing Analyst Ratings: A Detailed Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive ACADIA Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tessa Romero | JP Morgan | Lowers | Overweight | $25.00 | $29.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $30.00 | $40.00 |
| David Hoang | Citigroup | Lowers | Buy | $30.19 | $38.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $30.00 | $35.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $25.00 | $39.00 |
| Jason Butler | JMP Securities | Lowers | Outperform | $39.00 | $44.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $37.00 | $42.00 |
| Joel Beatty | Baird | Lowers | Outperform | $31.00 | $40.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $19.00 | $25.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $30.00 | $33.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $33.00 | $40.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Ami Fadia | Needham | Lowers | Buy | $32.00 | $36.00 |
| Tessa Romero | JP Morgan | Lowers | Overweight | $29.00 | $32.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Gregory Renza | RBC Capital | Lowers | Outperform | $35.00 | $36.00 |
| Uy Ear | Mizuho | Lowers | Buy | $39.00 | $40.00 |
| Ami Fadia | Needham | Lowers | Buy | $36.00 | $37.00 |
| Jason Butler | JMP Securities | Maintains | Market Outperform | $42.00 | - |
| Jay Olson | Oppenheimer | Maintains | Perform | $25.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Joel Beatty | Baird | Announces | Outperform | $40.00 | - |
| Joseph Stringer | Needham | Announces | Buy | $37.00 | - |
| Uy Ear | Mizuho | Raises | Buy | $40.00 | $35.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ACADIA Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of ACADIA Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into ACADIA Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
Discovering ACADIA Pharmaceuticals: A Closer Look
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Understanding the Numbers: ACADIA Pharmaceuticals's Finances
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: ACADIA Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 69.27%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.82%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 6.63%. This signifies efficient management of assets and strong financial health.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
